Translate Bio is set to carry out a first-in-human clinical trial of MRT5005 to treat patients with cystic fibrosis (CF), following approval from the US Food and Drug Administration (FDA).

Prior to granting the approval, the FDA reviewed an Investigational New Drug (IND) application submitted by Translate Bio.

The randomised, placebo-controlled trial will enrol a minimum of 32 adult patients with CF who have at least one Class I or Class II mutation.

“It will be the first mRNA therapeutic to enter the clinic with targeted delivery to the lung.”

Its primary endpoint is the safety and tolerability of single and multiple escalating doses of MRT5005 administered by nebulisation.

The trial will also measure forced expiratory volume in one second (FEV1) – a well-defined and accepted endpoint measuring lung function – at scheduled timepoints.

Translate Bio CEO Ronald Renaud said: “As our first IND submission and the first clinical trial to evaluate a product candidate derived from our mRNA technology (MRT) platform, this is a significant milestone for the company.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

“It also represents a pivotal time in the mRNA field as it will be the first mRNA therapeutic to enter the clinic with targeted delivery to the lung.”

Cystic Fibrosis Foundation Therapeutics Development Network is also involved in the trial, which intends to begin dosing patients within this year.

CF is caused by genetic mutations that lead to dysfunctional or absent CFTR protein. It is estimated to be the most common fatal inherited disease in the US, affecting more than 30,000 patients in the country and 70,000 patients worldwide.

MRT5005 is a clinical-stage mRNA product candidate designed to address the primary cause of CF by delivering mRNA encoding fully functional cystic fibrosis transmembrane conductance regulator (CFTR) protein to the lung epithelial cells through nebulisation.